In vitro cytotoxicity of Phortress against colorectal cancer

International Journal of Oncology

Volumn 29, Issue 5, 2006, Pages 1287-1294

  Mukherjee, Abhik ^a   Martin, Stewart Graham ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anti angiogenesis; Chemotherapy; Colorectal cancer; Phortress

Indexed keywords

5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; CYCLOHEXANE DERIVATIVE; FUMAGILLIN; PACLITAXEL; PRODRUG; SESQUITERPENE; THIAZOLE DERIVATIVE; UNSATURATED FATTY ACID;

ANGIOGENESIS; ARTICLE; BIOASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECT; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; TUMOR CELL LINE;

BIOLOGICAL ASSAY; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLOHEXANES; ENDOTHELIAL CELLS; FATTY ACIDS, UNSATURATED; FIBROBLASTS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL; PRODRUGS; SESQUITERPENES; THIAZOLES;

EID: 39049180808     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.5.1287     Document Type: Article

References (30)

1. Bradshaw TD and Westwell AD: The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem 11: 1009-1021, 2004.
2. Trapani V, Patel V, Leong CO, et al: DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 88: 599-605, 2003.
3. Bradshaw TD, Bibby MC, Double JA, et al: Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 1: 239-246, 2002.
4. Brantley E, Trapani V, Alley MC, et al: Fluorinated 2-(4-amino-3- methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos 32: 1392-1401, 2004.
5. Leong CO, Gaskell M, Martin EA, et al: Antitumour 2-(4-aminophenyl) benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 88: 470-477, 2003.
6. Leong CO, Suggitt M, Swaine DJ, Bibby MC, Stevens MF and Bradshaw TD: In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazoles. Mol Cancer Ther 3: 1565-1575, 2004.
7. Jaffe EA, Nachman RL, Becker CG and Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756, 1973.
8. Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J and Martin SG: Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer 92: 350-358, 2005.
9. Carmichael J, De Graff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
10. Carmichael J, De Graff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47: 943-946, 1987. (Pubitemid 17027906)
11. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H and Deppe G: Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer 70: 214-220, 1997.
12. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104-1109, 1993.
13. Freshney RI: Culture of Animal Cells: A Manual of Basic Technique. 3rd edition. Wiley Liss, New York, pp200-201, 1994.
14. Dicker AP, Williams TL and Grant DS: Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24: 438-442, 2001.
15. Ponce ML: In vitro Matrigel angiogenesis assays. In: Angiogenesis Protocols. Murray JC (ed.) Humana Press, Totowa, NJ, pp205-212, 2000.
16. Banerjee S, Fallis AG and Brown DL: Differential effects of taxol on two human cancer cell lines. Oncol Res 9: 237-248, 1997. (Pubitemid 127825976)
17. Valenti AM, Niero A, Monti G, Marangolo F and Marangolo M: Paclitaxel and N-methylformamide: in vitro interactions in human colon cancer cell line. Anticancer Res 17A: 2491-2497, 1997. (Pubitemid 27352642)
18. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.
19. Iwahana M, Utoguchi N, Mayumi T, Goryo M and Okada K: Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors. Anticancer Res 18C: 2977-2980, 1998. (Pubitemid 28388801)
20. Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990. (Pubitemid 120015110)
21. Hasan J, Shnyder SD, Bibby M, Double JA, Bicknel R and Jayson GC: Quantitative angiogenesis assays in vivo - a review. Angiogenesis 7: 1-16, 2004. (Pubitemid 39127766)
22. Takamiya Y, Brem H, Ojeifo J, Mineta T and Martuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34: 869-875, 1994. (Pubitemid 24130067)
23. Chabner BA and Longo DL: Preclinical aspects of drug discovery and development. In: Cancer Chemotherapy and Biotherapy. 3rd edition. Lippincott, Williams and Wilikins, Philadelphia, PA, lwwoncology.com, 2002.
24. Annas A, Brittebo E and Hellman B: Evaluation of benzo(a) pyrene-induced DNA damage in human endothelial cells using alkaline single cell gel electrophoresis. Mutat Res 471: 145-155, 2000.
25. Stegeman JJ, Hahn ME, Weisbrod R, et al: Induction of cytochrome P4501A1 by aryl hydrocarbon receptor agonists in porcine aorta endothelial cells in culture and cytochrome P4501A1 activity in intact cells. Mol Pharmacol 47: 296-306, 1995.
26. Celander M, Weisbrod R and Stegeman JJ: Glucocorticoid potentiation of cytochrome P4501A1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin in porcine and human endothelial cells in culture. Biochem Biophys Res Commun 232: 749-753, 1997.
27. Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA and Stevens MF: Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60: 5196-5203, 2000.
28. Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MF and Bradshaw TD: Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 61: 13-19, 2002. (Pubitemid 34049507)
29. Bradshaw TD, Chua MS, Orr S, Matthews CS and Stevens MF: Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445). Br J Cancer 83: 270-277, 2000. (Pubitemid 30411729)
30. Fichtner I, Monks A, Hose C, Stevens MF and Bradshaw TD: The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models. Breast Cancer Res Treat 87: 97-107, 2004. (Pubitemid 39237787)